Cost-Effectiveness of Ivabradine in the Treatment of Chronic Heart Failure

被引:12
作者
Adena, Michael A. [1 ]
Hamann, Gary [2 ]
Sindone, Andrew P. [3 ,4 ]
机构
[1] Datalyt Pty Ltd, 19-12 Trevillian Quay, Kingston, ACT 2604, Australia
[2] Servier Labs Aust Pty Ltd, Melbourne, Vic, Australia
[3] Concord Hosp, Heart Failure Unit, Sydney, NSW, Australia
[4] Concord Hosp, Dept Cardiac Rehabil, Sydney, NSW, Australia
关键词
Ivabradine; Heart failure; Cost effectiveness; Economic evaluation; Australia; Quality-Adjusted Life Years; MANAGEMENT; AUSTRALIA; IMPACT;
D O I
10.1016/j.hlc.2018.01.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background In the Systolic Heart failure treatment with the I-f inhibitor Trial (SHIFT) randomised placebo-controlled trial, ivabradine was shown to reduce hospital admissions for worsening heart failure (HF) and deaths due to HF in patients with symptomatic systolic HF and an elevated resting heart rate (HR). This analysis evaluates the cost effectiveness of adding ivabradine to optimal standard HF treatment in patients with a HR >= 77 bpm. Methods A Markov model was developed to assess the impact of ivabradine on mean survival and quality of life over a patient's lifetime (10 years). The hospitalisation and death rates were calculated using patient-level data from SHIFT. The reduction in quality of life due to HF hospitalisations was estimated directly from EQ-5D data collected in SHIFT. Australian costs were applied to the resource use from SHIFT. Results The modelled mean increase in survival with ivabradine was 0.115 years. The mean increase in quality-adjusted survival was 0.108 years. The average cost of ivabradine was A$2,957 and the cost savings associated with a reduction in HF hospitalisations was A$1,344. The cost per quality adjusted life year gained (QALYG) was A$14,905. The conservative approach to the modelled evaluation, as well as results of the sensitivity analysis, demonstrates that ivabradine is likely to be cost-effective in this indication. Conclusions The conservative approach to the modelled evaluation, as well as results of the sensitivity analysis, demonstrates that ivabradine is a cost-effective treatment in the Australian setting for HF patients with a HR > 77 bpm on optimal standard therapy with a cost per QALYG similar or lower than that for other publicly funded treatments.
引用
收藏
页码:414 / 422
页数:9
相关论文
共 50 条
[41]   A cost-effectiveness analysis of bisoprolol for heart failure [J].
Varney, S .
EUROPEAN JOURNAL OF HEART FAILURE, 2001, 3 (03) :365-371
[42]   Dapagliflozin cost-effectiveness analysis in heart failure patients in Egypt [J].
Abdelhamid, Magdy ;
Elsisi, Gihan Hamdy ;
Seyam, Ahmed ;
Shafie, Ahmed ;
Kirollos, Mary ;
Emad, Sandy ;
Mansy, Shady ;
Sobhy, Mohamed .
JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) :450-456
[43]   COST-EFFECTIVENESS OF TELEHEALTH INTERVENTIONS FOR CHRONIC HEART FAILURE PATIENTS: A LITERATURE REVIEW [J].
Grustam, Andrija S. ;
Severens, Johan L. ;
van Nijnatten, Jan ;
Koymans, Ron ;
Vrijhoef, Hubertus J. M. .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2014, 30 (01) :59-68
[44]   Ivabradine, heart failure and chronic kidney disease [J].
Di Lullo, Luca ;
Bellasi, Antonio ;
Russo, Domenico ;
Cozzolino, Mario ;
Ronco, Claudio ;
Santoboni, Alberto ;
Barbera, Giovanni .
NEPHROLOGY @ POINT OF CARE, 2015, 1 (01) :E39-E43
[45]   Clinical effectiveness and cost-effectiveness of ambulatory heart failure nurse-led services: an integrated review [J].
Andrea Driscoll ;
Lan Gao ;
Jennifer J. Watts .
BMC Cardiovascular Disorders, 22
[46]   Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal [J].
Borges, Margarida ;
Afonso-Silva, Marta ;
Laires, Pedro A. ;
Gouveia, Miguel ;
Alarcao, Joana ;
Ascencao, Raquel ;
Costa, Joao .
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (02) :199-205
[47]   A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction [J].
Tafazzoli, Ali ;
Reifsnider, Odette S. ;
Bellanca, Leana ;
Ishak, Jack ;
Carrasco, Marc ;
Rakonczai, Pal ;
Stargardter, Matthew ;
Linden, Stephan .
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2023, 24 (09) :1441-1454
[48]   Cost-Effectiveness Analysis of Sacubitril/Valsartan Compared to Enalapril for Heart Failure Patients in Indonesia [J].
Zakiyah, Neily ;
Sinuraya, Rano K. ;
Kusuma, Arif S. W. ;
Suwantika, Auliya ;
Lestari, Keri .
CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 :863-872
[49]   Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes [J].
van Giessen, Anoukh ;
Boonman-de Winter, Leandra J. M. ;
Rutten, Frans H. ;
Cramer, Maarten J. ;
Landman, Marcel J. ;
Liem, Anho H. ;
Hoes, Arno W. ;
Koffijberg, Hendrik .
CARDIOVASCULAR DIABETOLOGY, 2016, 15
[50]   The cost-effectiveness of real-time pulmonary artery pressure monitoring in heart failure patients: a European perspective [J].
Cowie, Martin R. ;
Simon, Marcus ;
Klein, Liviu ;
Thokala, Praveen .
EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 (05) :661-669